Abpro Holdings, Inc.

ABP

US0008472021

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 18/02/2026			5-day change	1st Jan Change
0.5810 ^USD	-2.75%		-54.25%	-86.26%

02-03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
01-23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI

Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance

Published on 01/06/2026 at 01:21 pm GMT

MT Newswires

Latest news about Abpro Holdings, Inc.

02-03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
01-23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
01-16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
12-15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
11-14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing	RE
22/10/25	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing	RE
02/10/25	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025	CI
13/08/25	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/05/25	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/04/25	Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	CI
15/04/25	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.

Employees

Sector

Biotechnology & Medical Research

More about the company